Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 2/20 | 0.65 |
| ▸ | GAA | P10253 | 2/20 | 0.65 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.55 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.55 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.55 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | ITGB3 | P05106 | 3/20 | 0.44 |
| ▸ | ITGA2B | P08514 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4292207 | 0.97 | PKM (0.69) | PKMGAAHDAC6HDAC1HDAC8 | |
| SCHEMBL26915184 | 0.89 | HDAC6 (0.62) | PKMGAAHDAC6HDAC1HDAC8 | |
| SCHEMBL18894019 | 0.89 | HDAC6 (0.62) | PKMGAAHDAC6HDAC1HDAC8 | |
| SCHEMBL4281521 | 0.89 | HDAC6 (0.62) | PKMGAAHDAC6HDAC1HDAC8 | |
| SCHEMBL4292503 | 0.89 | PKM (0.72) | PKMGAAHDAC6HDAC1HDAC8 | |
| SCHEMBL4284045 | 0.89 | GAA (0.60) | PKMGAAHDAC6HDAC1HDAC8 | |
| SCHEMBL4287881 | 0.86 | PKM (0.57) | PKMGAAHDAC6HDAC1HDAC8 | |
| SCHEMBL4281530 | 0.86 | GAA (0.56) | PKMGAAHDAC6HDAC1HDAC8 | |
| SCHEMBL4286523 | 0.84 | PKM (0.54) | PKMGAAHDAC6HDAC1HDAC8 | |
| SCHEMBL4288914 | 0.83 | HDAC6 (0.53) | PKMGAAHDAC6HDAC1HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227560-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-10 | — | — | US | disclosed |
| US-20090156612-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
| WO-2008139941-A1 | SUBSTITUTED IMIDAZOLE COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156612-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | PKM 847/4885GAA 1381/4885HDAC6 903/4885 |
| US-20090227560-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | PKM 847/4885GAA 1381/4885HDAC6 903/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.